{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:03:21Z","timestamp":1791443001688,"version":"4.3.3"},"reference-count":64,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2024,4,2]]},"DOI":"10.1080\/14737175.2024.2325655","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T09:23:02Z","timestamp":1709716982000},"page":"325-332","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults"],"prefix":"10.1080","volume":"24","author":[{"given":"Giovanna","family":"Cirnigliaro","sequence":"first","affiliation":[{"name":"Department of Biomedical and Clinical Sciences (DIBIC), Department of Psychiatry, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Battini","sequence":"additional","affiliation":[{"name":"Pharmacovigilance &amp; Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Castiglioni","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences (DIBIC), Department of Psychiatry, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"Renne","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences (DIBIC), Department of Psychiatry, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Mosini","sequence":"additional","affiliation":[{"name":"Pharmacovigilance &amp; Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cheli","sequence":"additional","affiliation":[{"name":"Pharmacovigilance &amp; Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Carnovale","sequence":"additional","affiliation":[{"name":"Pharmacovigilance &amp; Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Dell\u2019Osso","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences (DIBIC), Department of Psychiatry, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy"},{"name":"Department of Psychiatry and Behavioral Sciences, Bipolar Disorders Clinic, Stanford Medical School, Stanford University, Stanford, CA, USA"},{"name":"CRC \u201cAldo Ravelli\u201d for Neurotechnology &amp; Experimental Brain Therapeutics, University of Milan, Milan, Italy"},{"name":"Centro per lo studio dei meccanismi molecolari alla base delle patologie neuro-psico-geriatriche, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"e_1_3_4_4_1","unstructured":"Schizophrenia Global Prevalence [Internet]. [cited 2023 Nov 21]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004867416641195"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901"},{"key":"e_1_3_4_7_1","unstructured":"National Collaborating Centre for Mental Health (UK). Psychosis and schizophrenia in adults: treatment and management: updated edition 2014 [internet]. London: National Institute for Health and Care Excellence (UK); 2014 [cited 2023 Nov 19]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK248060\/"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.05.011"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/21.3.419"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15032su1"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17091001"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbu164"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717000873"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00779-5"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1379412"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab071"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923080-00002"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291721000180"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2023.04.018"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)00085-7"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2011.143"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4399"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145712001277"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00005-6"},{"key":"e_1_3_4_27_1","doi-asserted-by":"crossref","unstructured":"Boyer L Falissard B Nuss P et al. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12 373 patients with schizophrenia-spectrum disorders. Mol Psychiatry [Internet]. 2023 [cited 2023 Nov 19]; Available from: https:\/\/www.nature.com\/articles\/s41380-023-02175-z","DOI":"10.1038\/s41380-023-02175-z"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00900-y"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2022.20.1.118"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00643.x"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.12.010"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.07.011"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1882412"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16m11308"},{"key":"e_1_3_4_35_1","unstructured":"Janssen Pharmaceuticals Companies. Invega Sustenna (paliperidone palmitate) [prescribing information] [internet]. [cited 2022 Apr 23]."},{"key":"e_1_3_4_36_1","doi-asserted-by":"crossref","unstructured":"Vats A Nair AR Bandhu AK et al. Treatment of patients with schizophrenia and comorbid chronic hepatitis with paliperidone: a systematic review. Cureus [Internet]. 2023 [cited 2023 Nov 19]; Available from: https:\/\/www.cureus.com\/articles\/128339-treatment-of-patients-with-schizophrenia-and-comorbid-chronic-hepatitis-with-paliperidone-a-systematic-review","DOI":"10.7759\/cureus.34234"},{"key":"e_1_3_4_37_1","first-page":"42","article-title":"Long-acting injectable paliperidone palmitate: a review of efficacy and safety","volume":"47","author":"Morris MT","year":"2017","unstructured":"Morris MT, Tarpada SP. Long-acting injectable paliperidone palmitate: a review of efficacy and safety. Psychopharmacol Bull. 2017;47:42\u201352.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.08.015"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09584"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.597"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/eip.12685"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0241"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw018"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000190"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2263650"},{"key":"e_1_3_4_46_1","unstructured":"Janssen Pharmaceuticals Companies. Invega Trinza (paliperidone palmitate) [Prescribing Information] [Internet]. [cited 2022 Apr 23]. Available from: http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/INVEGA+TRINZA-pi.pdf.44"},{"key":"e_1_3_4_47_1","unstructured":"Janssen Pharmaceuticals. Invega Hafyera (paliperidone palmitate) [prescribing information] [Internet]. [cited 2022 Apr 20]. Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/INVEGA+HAFYERA-pi.pdf.46"},{"key":"e_1_3_4_48_1","unstructured":"European Medicines Agency. Xeplion (paliperidone palmitate) [summary of product characteristics] [Internet]. [cited 2022 Apr 23]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeplion-epar-productinformation_en.pdf.43"},{"key":"e_1_3_4_49_1","unstructured":"European Medicines Agency. Trevicta (paliperidone palmitate) [summary of product characteristics] [Internet]. [cited 2022 Apr 23]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trevicta-epar-product-information_en.pdf.45"},{"key":"e_1_3_4_50_1","unstructured":"European Medicines Agency. Byannli (paliperidone palmitate) [summary of product characteristics] [Internet]. [cited 2022 Apr 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/byannli-previously-paliperidone-janssen-cilag-international-epar-product-information_en.pdf"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2228686"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1965-1"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.018275"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.55"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1549489"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S400342"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyad028"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14754"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2020.02.022"},{"key":"e_1_3_4_62_1","unstructured":"Research J Development LA-D-B Randomized active-controlled parallel-group study of paliperidone palmitate 6-month formulation. ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2024 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03345342NLMIdentifier:NCT03345342"},{"key":"e_1_3_4_63_1","unstructured":"Janssen Research Development LS-A Open-label extension to a double-blind randomized active-controlled parallel-group study of paliperidone palmitate 6-month formulation. ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2024 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04072575NLMIdentifier:NCT04072575"},{"key":"e_1_3_4_64_1","unstructured":"BYANNLI Assesment report [Internet]. [cited 2023 Nov 21]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/byannli-h-c-5486-x-02-g-epar-assessment-report-variation_en.pdf"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1130636"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1177\/87551225231153541"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S395383"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-116492"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2024.2325655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T18:00:13Z","timestamp":1727200813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2024.2325655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,2]]}},"alternative-id":["10.1080\/14737175.2024.2325655"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2024.2325655","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}